Treatment of Iron Deficiency
The gold standard treatment for iron deficiency is oral iron supplementation with 50-100 mg of elemental iron once daily, taken in the fasting state (morning), with continuation for 3 months after hemoglobin normalization to replenish iron stores. 1
Oral Iron Therapy: First-Line Treatment
Dosing Recommendations
- Optimal dosing strategy:
Population-Specific Dosing (CDC Recommendations)
- Nonpregnant women and adolescent girls: 60-120 mg daily
- School-age children: 60 mg daily
- Adolescent boys: 120 mg daily
- Pregnant women (preventive): 30 mg daily
- Pregnant women (treatment): 60-120 mg daily 1
Formulations
- Ferrous sulfate (65 mg elemental iron per tablet) is the simplest, least expensive, and most commonly prescribed form 1, 3
- Other options include ferrous salts and ferric complexes with polysaccharides 3
- Extended-release formulations may reduce gastrointestinal side effects 4
Monitoring Response
- Check hemoglobin after 2-4 weeks of treatment
- Critical decision point: Increase in hemoglobin of ≥10 g/L after 2 weeks strongly predicts successful treatment (sensitivity 90.1%, specificity 79.3%) 1
- Continue monitoring every 4 weeks until hemoglobin normalizes
- After normalization, continue iron for 3 months to replenish stores
- Long-term follow-up with iron studies every 3 months during maintenance phase 1
When to Consider Intravenous Iron
Intravenous iron should be used when:
- Oral iron is not tolerated
- No hemoglobin increase of at least 10 g/L after 2 weeks of oral therapy
- Malabsorption conditions present (celiac disease, post-bariatric surgery)
- Chronic inflammatory conditions (IBD, CKD, heart failure, cancer)
- Ongoing blood loss exceeding oral replacement capacity
- Second and third trimesters of pregnancy when rapid repletion needed 1, 5
IV Iron Options
- Ferric carboxymaltose: Maximum single dose 1000 mg, infused over 15 minutes 1
- Iron sucrose: 200 mg per injection over 10-30 minutes 1
- Iron dextran: Can replenish iron in a single infusion but carries risk of serious reactions (0.6-0.7%) 1
Identifying and Addressing Underlying Causes
Essential evaluations based on patient demographics:
- Men and postmenopausal women: Evaluate for gastrointestinal blood loss with upper GI endoscopy and colonoscopy 1
- Premenopausal women: Assess for heavy menstrual bleeding 1
- All patients: Screen for malabsorption conditions and evaluate dietary intake patterns 1
- Consider testing for H. pylori 1
- Screen for celiac disease with tTG antibodies, especially in premenopausal women 1
Common Pitfalls to Avoid
- Inadequate monitoring: Failing to check hemoglobin response after 2 weeks may delay recognition of treatment failure 1
- Premature discontinuation: Stopping iron once hemoglobin normalizes without continuing for 3 months to replenish stores 1
- Overuse of blood transfusion: Should be reserved for severe symptomatic anemia or circulatory compromise 1
- Ignoring non-response: May indicate non-compliance, malabsorption, continued bleeding, or concurrent deficiencies 1
- Using inappropriate ferritin cutoffs in patients with inflammation (should use transferrin saturation <20% when ferritin is 30-100 μg/L) 1
- Excessive dosing: Traditional high-dose daily regimens (150-200 mg) lead to lower fractional absorption and more side effects; alternate-day dosing may improve absorption and reduce side effects 2, 6